Achillion
Pharmaceuticals Inc. (Nasdaq: ACHN) reported positive interim results from a
Phase II study of the hepatitis C treatment ACH-3102. The stock price soared $2.37 to close at $14.85.
Achillion reports upbeat interim results
November 12, 2014 at 17:21 PM EST
